Cel-sci

(NYSEMKT) CVM

Current Price$1.27

Market Cap$20.45M

Since IPO (1992)-100%

5 Year-100%

1 Year-72%

1 Month+6%

Cel-sci last closing stock price
Metric	Price	Date
Last close	USD 1.17	2026-07-17

Cel-sci stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-15.22%	USD 1.38	2026-07-10
1 month	+6.36%	USD 1.10	2026-06-17
3 month	-76.36%	USD 4.95	2026-04-17
Year to date	-77.76%	USD 5.26	2025-12-31
1 year	-71.94%	USD 4.17	2025-07-17
3 year	-98.22%	USD 65.70	2023-07-18
5 year	-99.51%	USD 237.90	2021-07-16
Since inception	-100%	USD 234,398.44	1992-02-10

Cel-sci Financials at a Glance

Market Cap

$20.45M

Revenue (TTM)

$0.00

Net Income (TTM)

-$22.70M

EPS (TTM)

-$3.48

P/E Ratio

-0.34

Dividend

$0.00

Beta (Volatility)

1.25 (Average)

Dividend

$0.00

Beta (Volatility)

1.25 (Average)

Price

$1.27

Volume

6,576

Open

$1.22

Price

$1.27

Volume

6,576

Open

$1.22

Previous Close

$1.27

Daily Range

$1.13 - $1.27

52-Week Range

$0.89 - $13.48

Estimated Earnings Date

Aug 17, 2026

Dividend

$0.00

Beta (Volatility)

1.25 (Average)

Price

$1.27

Volume

6,576

Open

$1.22

Previous Close

$1.27

Daily Range

$1.13 - $1.27

52-Week Range

$0.89 - $13.48

Estimated Earnings Date

Aug 17, 2026

CVM News

Why CEL-SCI Stock Soared Today

Keith SpeightsJul 7, 2021

Will All End Well for This Popular Reddit Biotech?

Zhiyuan SunJun 30, 2021

Can You Count on This Popular Reddit Cancer-Treatment Stock?

Zhiyuan SunJun 5, 2021

Here’s What’s Behind The Hottest Battleground Stock in Cancer Treatment

Zhiyuan SunApr 24, 2020

Charts going up with man looking thru skyscraper window

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cel-sci

CEL-SCI develops treatments that help the immune system fight cancer and infections. Its main product, Multikine, targets head and neck cancer patients before surgery. LEAPS technology aims to treat diseases like arthritis and viral infections.

Lab Bench to Bedside: What CEL-SCI Sells

Multikine immunotherapy: Investigational treatment for head and neck cancer, used before standard therapies. 0% of revenue (pre-revenue).
LEAPS platform: Early-stage technology to train immune cells against infections and autoimmune diseases. 0% of revenue.
Rheumatoid arthritis candidates: CEL-2000 and CEL-4000, both in pre-clinical development for joint inflammation.
Infectious disease candidates: LEAPS-H1N1-DC for influenza and LEAPS COV-19 for COVID-19, both in early research.
Manufacturing services: In-house facility for producing Multikine for trials and potential future sales.

Growth Moves: CEL-SCI’s Expansion Playbook

Launched confirmatory Multikine study in Q1 2025 to support regulatory approval.
Expanded manufacturing facility near Baltimore, Maryland, completed in 2021.
Formed licensing deals with Teva Pharmaceutical, Orient Europharma, and Byron Biopharma for future product distribution.
Partnered with University of Georgia for LEAPS COVID-19 research.
Entered Asia-Pacific, Israel, Turkey, and South Africa markets through licensing agreements with local partners.

What Makes CEL-SCI Stand Out

CEL-SCI focuses on patients not well served by current cancer immunotherapies. Its approach uses the immune system before other treatments begin. The company controls its own manufacturing, supporting future scale-up if products are approved.

Five Things You Need to Know

No product revenue reported for 2023, 2024, or Q3 2025.
Net loss was $5 million in Q3 2025, improved 17.7% from Q3 2024.
Cash used in operations was $4 million in Q3 2025, down 13.3% year-over-year.
R&D spending focused approximately 99% on Multikine in 2024.
Raised $21.2 million in 2024 through stock sales and warrants.

Bottom Line

CEL-SCI remains a pre-revenue biotech focused on immunotherapy innovation. Its future depends on clinical trial progress and continued access to funding.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Geert R. Kersten, MBA

Website

www.cel-sci.com

Headquarters

Vienna, VA 22182, US

CVM Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-221.50%

Return on Capital

-97.90%

Return on Assets

-128.20%

Earnings Yield

-2.94%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$20.45M

Shares Outstanding

17.48M

Volume

6.58K

Avg. Volume

540.04K

Financials (TTM)

Gross Profit

-$6.55M

Operating Income

-$22.22M

EBITDA

-$18.35M

Operating Cash Flow

-$16.65M

Capital Expenditure

-$5.15K

Free Cash Flow

-$16.66M

Cash & ST Invst.

$1.89M

Total Debt

$8.51M

Cel-sci Performance Analysis

Cel-sci annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-09-30	USD 0	N/A
2023	2023-09-30	USD 0	N/A
2024	2024-09-30	USD 0	N/A
2025	2025-09-30	USD 0	N/A

Cel-sci sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-06-30	N/A
Q4	2025-09-30	N/A
Q1	2025-12-31	N/A
Q2	2026-03-31	N/A

Cel-sci annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-09-30	USD -26.16	-2.5%
2023	2023-09-30	USD -21.83	-16.6%
2024	2024-09-30	USD -14.94	-31.5%
2025	2025-09-30	USD -6.27	-58.1%

Cel-sci sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-06-30	41.6%
Q4	2025-09-30	44.1%
Q1	2025-12-31	10.5%
Q2	2026-03-31	1.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$956.40K

+76.2%

Gross Margin

0.00%

N/A

Market Cap

$20.45M

N/A

Market Cap/Employee

$475.54K

N/A

Employees

N/A

Net Income

-$5.47M

+16.8%

EBITDA

-$4.39M

+19.0%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$1.89M

-1.7%

Total Debt

$8.51M

-19.2%

Accounts Receivable

$0.00

N/A

Inventory

$281.46K

-68.1%

Long Term Debt

$5.90M

-27.9%

Short Term Debt

$2.61M

+11.3%

Return on Assets

-1.28%

N/A

Return on Invested Capital

-1.72%

N/A

Free Cash Flow

-$4.02M

+8.0%

Operating Cash Flow

-$4.02M

+8.0%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

BRNSBarinthus Biotherapeutics plc

BRNSBarinthus Biotherapeutics plc$0.62+11.05%

ALGSAligos Therapeutics, Inc.

ALGSAligos Therapeutics, Inc.$5.28-8.01%

TPSTTempest Therapeutics, Inc.

TPSTTempest Therapeutics, Inc.$0.95-1.41%

FGENFibroGen, Inc.

FGENFibroGen, Inc.$9.07-1.63%

PDSBPDS Biotechnology Corporation

PDSBPDS Biotechnology Corporation$0.72-2.39%

INMBINmune Bio, Inc.

INMBINmune Bio, Inc.$1.99+4.74%

KZRKezar Life Sciences, Inc.

KZRKezar Life Sciences, Inc.$7.29+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

ZYBTZhengye Biotechnology

ZYBTZhengye Biotechnology$8.01+10.48%

AALAmerican Airlines Group

AALAmerican Airlines Group$15.14+0.01%

ACHRArcher Aviation

ACHRArcher Aviation$5.31+0.20%

IRENIren

IRENIren$40.20+0.20%

HLHecla Mining

HLHecla Mining$14.29-0.00%

TAT&T

TAT&T$21.95+0.01%

NOKNokia

NOKNokia$10.08-0.00%

Questions About CVM

What is the current price of Cel-sci?

Cel-sci is trading at $1.27 per share.

What is the 52-week range for Cel-sci?

Over the past 52 weeks, Cel-sci has traded between $0.89 and $13.48.

How much debt does Cel-sci have?

As of the most recent reporting period, Cel-sci reported total debt of $8.51M.

How much cash does Cel-sci have on hand?

Cel-sci reported $1.89M in cash and cash equivalents in its most recent financial results.

What is Cel-sci’s dividend yield?

Cel-sci does not currently have a dividend yield.

Cel-sci

Cel-sci Financials at a Glance

CVM News

Why CEL-SCI Stock Soared Today

Will All End Well for This Popular Reddit Biotech?

Can You Count on This Popular Reddit Cancer-Treatment Stock?

Here’s What’s Behind The Hottest Battleground Stock in Cancer Treatment

These 3 Biotech Stocks Skyrocketed Last Week -- Are They Buys Now?

One Biotech Stock to Avoid

An Inside Look at Biotech Investing, Part 2

CEL-SCI Investors Cheer a Bit Too Loudly

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Cel-sci

Lab Bench to Bedside: What CEL-SCI Sells

Growth Moves: CEL-SCI’s Expansion Playbook

What Makes CEL-SCI Stand Out

Five Things You Need to Know

Bottom Line

CVM Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Cel-sci Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About CVM

What is the current price of Cel-sci?

What is the 52-week range for Cel-sci?

How much debt does Cel-sci have?

How much cash does Cel-sci have on hand?

What is Cel-sci’s dividend yield?

Premium Investing Services